Meeting Banner
Abstract #5113

Long-term prognostic value of whole-body MRI fat fraction signal changes following initial Bortezomib treatment of patients with multiple myeloma

Arash Latifoltojar1, Margaret Hall-Craggs1, Alan Bainbridge2, Neil Rabin2, Rakesh Popat1, Ali Rismani2, Kwee Yong1, and Shonit Punwani1

1University College London, London, United Kingdom, 2University College London Hospital, United Kingdom

Quantitative MRI assessment of treatment response using advanced novel imaging techniques have shown promises for monitoring outcome in patients with symptomatic multiple myeloma (MM), undergoing intensive chemotherapy.

In this work we are investiagting the potential of whole-body mDixon MRI's signal fat fraction early changes as a prognostic imaging biomarker for long-term follow-up of MM patients.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords